| Bioactivity | Flupentixol is an orally active D1/D2 dopamine receptor antagonist and new PI3K inhibitor (PI3Kα IC50=127 nM). Flupentixol shows anti-proliferative activity to cancer cells and induces apoptosis. Flupentixol can also be used in schizophrenia, anxiolytic and depressive research[1][2][3]. |
| Invitro | Flupentixol (2.5-40 μM; 72 h) treatment inhibits the viability of lung cancer cells in a dose-dependent manner[3].Flupentixol (2.5-40 μM; 24 h) induces apoptosis in lung cancer cells[3].Flupentixol (2.5-15 μM; 24 h) inhibits p-AKT and Bcl-2 expression levels[3]. Cell Viability Assay[3] Cell Line: |
| Name | Flupentixol dihydrochloride |
| CAS | 2413-38-9 |
| Formula | C23H27Cl2F3N2OS |
| Molar Mass | 507.44 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | 4°C, sealed storage, away from moisture and light *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light) |
Flupentixol dihydrochloride
CAS: 2413-38-9 F: C23H27Cl2F3N2OS W: 507.44
Flupentixol is an orally active D1/D2 dopamine receptor antagonist and new PI3K inhibitor (PI3Kα IC50=127 nM). Flupenti
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.